1.Altman, D. G.Statistics in medical journals. Statistics in Medicine, 1982, 1, 59–71.
2.Anders, G. Testing a new drug entails daunting costs and clashing interests. Wall Street Journal, 01 7, 1994, 5–7.
3.Anderson, J. J., Felson, D. T., & Meenan, R. F.Secular changes in published clinical trials of second-line agents in rheumatoid arthritis. Journal of Laboratory and Clinical Medicine, 1991, 34, 1304–09.
4.Angell, M., & Relman, A. S.Redundant publication. New England Journal of Medicine, 1989, 320, 1212–14.
5.Anturane Reinfarction Trial Policy Committee. The Anturane reinfarction trial: Reevaluation of outcome. New England Journal of Medicine, 1982, 306, 1005–08.
6.Assmann, G., & Brewer, J.Genetic (primary) forms of hypertriglyceridemia. American Journal of Cardiology, 1991, 68, 13A–16A.
7.Bailey, B. J.Duplicate publication in otolaryngology: Head and neck surgery. Program and abstracts of the First International Congress on Peer Review in Biomedical Publication, Chicago, 1989.
8.Bero, L. A.Gailbraith, A., & Rennie, D.Sponsored symposia and their publication in medical journals, University of California-San Francisco, Institute for Health Policy Studies, 1992, monograph.
9.Bero, L. A.Gailbraith, A., & Rennie, D.The publication of sponsored symposiums in medical journals. New England Journal of Medicine, 1992, 327, 1135–40.
10.Bero, L. A., & Glantz, S. G.Tobacco industry response to a risk assessment of environmental tobacco smoke. Tobacco Control, 1993, 2, 103–13.
11.Bierut, M. B.The Prescription Drug User Fee Act of 1992: Speeding up the drug approval process. Healthspan, 1992, 9, 12–14.
12.Bobbio, M., Demichelis, B., & Giustetto, G.Completeness of reporting trial results: Effect on physicians’ willingness to prescribe. Lancet, 1994, 343, 1209–11.
13.Bond, G. G.Ethical issues relating to the conduct and interpretation of epidemiologic research in private industry. Journal of Clinical Epidemiology, 1991, 44, 29S–34S.
14.Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction [special report]. New England Journal of Medicine, 1989, 321, 406–12.
15.Carette, S., Bell, M. J., Reynolds, W. J., et al. Comparison of amitriptyline.cyclobenzaprine, and placebo in the treatment of fibromyalgia. Arthritis and Rheumatism, 1994, 37, 32–40.
16.Cavalli, F.Our policy regarding supplements of sponsored symposia. Annals of Oncology, 1993, 4, 99.
17.Chalmers, I.Underreporting research is scientific misconduct. Journal of the American Medical Association, 1990, 263, 1405–08.
18.Chalmers, I., Dickersin, K., & Chalmers, T. C.Getting to grips with Archie Cochrane’s agenda. British Medical Journal, 1992, 305, 786–88.
19.Chalmers, T. C., Frank, C. S., & Reitman, D.Minimizing the three stages of publication bias. Journal of the American Medical Association, 1990, 263, 1392–95.
20.Chalmers, T. C., Harry Smith, J., Blackburn, B., et al. A method for assessing the quality of a randomized control trial. Controlled Clinical Trials, 1981, 2, 31–49.
21.Charny, M.Publication bias [letter to the editor]. Lancet, 1991, 337, 1102.
22.Cho, M. K., & Bero, L. A.Instruments for assessing the quality of drug studies published in the medical literature. Journal of the American Medical Association, 1994, 272, 101–04.
23.Cho, M. K., & Bero, L. A.The quality of drug studies published in symposium proceedings. Annals of Internal Medicine, 1996, 124, 485–89.
24.Colditz, G. A., Miller, J. A., & Mosteller, F.How study design affects outcomes in comparisons of therapy, I: Medical. Statistics in Medicine, 1989, 8, 441–54.
25.Crevey, B. J., Dantzker, D. R., Bower, J. S., et al. Hemodynamic and gas exchange effects of intravenous diltiazem in patients with pulmonary hypertension. American Journal of Cardiology, 1982, 49, 578–83.
26.Criswell, L. A., Katz, P. P., & Tack, B. B.No firm basis to advocate auranofin in the treatment of juvenile rheumatoid arthritis [letter]. Arthritis and Rheumatism, 1991, 34, 934–35.
27.Croog, S. H., Levine, S., Testa, M. A., et al. The effects of antihypertensive therapy on the quality of life. New England Journal of Medicine, 1986, 314, 1657–64.
28.Davidson, R. A.Source of funding and outcome of clinical trials. Journal of General Internal Medicine, 1986, 1, 155–58.
29.Dickersin, K.Why register clinical trials? Revisited. Controlled Clinical Trials, 1992, 13, 170–77.
30.Dickersin, K., & Garcia-Lopez, F.Regulatory process affects clinical trial registration in Spain. Controlled Clinical Trials, 1992, 13, 507–12.
31.Dickersin, K., Min, Y-I., & Meinert, C. L.Factors influencing publication of research results: Follow-up of applications submitted to two institutional review boards. Journal of the American Medical Association, 1992, 267, 374–78.
32.Dieppe, P. A., Frankel, S. J., & Toth, B.Is research into the treatment of osteoarthritis with non-steroidal anti-inflammatory drugs misdirected? Lancet, 1993, 341, 353–54.
33.Dyer, C.GMC finds GPs guilty of fraud. British Medical Journal, 1994, 308, 1122.
34.Easterbrook, P. J., Berlin, J. A., Gopalan, R., & Matthews, D. R.Publication bias in clinical research. Lancet, 1991, 337, 867–72.
35.Epstein, W. V., & Criswell, L. A.Auranofin, methotrexate, but no placebo: Comment on the article by Williams et al. [letter]. Arthritis and Rheumatism, 1992, 35, 1406.
36.Evidence-Based Medicine Working Group. Evidence-based medicine: A new approach to teaching the practice of medicine. Journal of the American Medical Association, 1992, 268, 2420–25.
37.Farkouh, M. E., Lang, J. D., & Sackett, D. L.Thrombolytic agents: The science of the art of choosing the better treatment [editorial]. Annals of Internal Medicine, 1994, 120, 886–88.
38.FDA Division of Neuropharmacological Drug Products, O. o. N. D. E. Tacrine as a treatment for Alzheimer’s dementia: An interim report from the FDA. New England Journal of Medicine, 1991, 324, 349–52.
39.F-D-C Reports Inc. FDA advisory committee defers decision on IMREG-1. The Blue Sheet, 11 23, 1988, 31, 2–3.
40.F-D-C Reports Inc. FIAU investigators receive FDA ‘warning letters.’ The Blue Sheet, 1994, 337, 11–12.
41.F-D-C Reports Inc. HRG suing FDA for FIAU study records, data from other discontinued drug clinical trials. The Blue Sheet, 1994, 37, 7.
42.F-D-C Reports Inc. IMREG-1 AIDS clinical trial; FDA inspection raises questions about patient selection, record-keeping. The Blue Sheet, 11 2, 1988, 31, 4–5.
43.Fisch, C., & Knoebel, S. B.Electrocardiographic findings in sertraline depression trials. Drug Investigation, 1992, 4, 305–12.
44.Food and Drug Administration. Approved drug products with therapeutic equivalence, 12th ed.Washington, DC: Government Printing Office, 1992.
45.Food and Drug Administration. Guideline for the format and content of the clinical and statistical sections of an application. Center for Drug Evaluation and Research, Food and Drug Administration, 1988.
46.Food and Drug Administration. New drug and antibiotic regulations: Final rule. Federal Register, 1985, 50, 7452–519.
47.Forrow, L., Taylor, W. C., & Arnold, R. M.Absolutely relative: How research results are summarized can affect treatment decisions. American Journal of Medicine, 1992, 92, 121–24.
48.Frick, M. H., Elo, O., & Haapa, K.Helsinki heart study: Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. New England Journal of Medicine, 1987, 317, 1237–45.
49.Gardner, M. J.. & Bond, J.An exploratory study of statistical assessment papers published in the British Medical Journal. Journal of the American Medical Association, 1990, 263, 1355–57.
51.Giannini, E. H., Brewer, E. J., Kuzmina, N., et al. Auranofin in the treatment of juvenile rheumatoid arthritis. Arthritis and Rheumatism, 1990, 33, 466–76.
50.Giannini, E. H., & Brewer, E. J. Reply to letter. Arthritis and Rheumatism, 1991, 34.
52.Gottlieb, M. S., Zackin, R. A., Fiala, M., et al. Response to treatment with the leukocytederived immunomodulator IMREG-1 in immunocompromised patients with AIDS related complex. Annals of Internal Medicine, 1991, 115, 84–91.
53.Gøtzsche, P. C.Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal antiinflammatory drugs in rheumatoid arthritis. Controlled Clinical Trials, 1989, 10, 31–56.
54.Guyatt, G.Academic medicine and the pharmaceutical industry: A cautionary tale [editorial]. Canadian Medical Association Journal, 1994, 150, 951–53.
55.Guyatt, G. H., & Rennie, D.Users’ guides to the medical literature [editorial]. Journal of the American Medical Association, 1993, 270, 2096–97.
56.Guyatt, G. H., Sackett, D. L., & Cook, D. J.Users’ guides to the medical literature, II: How to use an article about therapy or prevention. Journal of the American Medical Association, 1993, 270, 2598–601.
57.Hardy, W. D.Foscarnet treatment of acyclovir-resistant herpes simplex virus infection in patients with acquired immunodeficiency syndrome: Preliminary results of a controlled, randomized, regimen-comparative trial. American Journal of Medicine, 1992, 92, 30S–35S.
58.Haynes, R. B.Clinical review articles. British Medical Journal, 1991, 304, 330–31.
59.Haynes, R. B., Mulrow, C. D., Huth, E. J., et al. More informative abstracts revisited. Annals of Internal Medicine, 1990, 113, 69–76.
60.Hemminki, E.Quality of clinical trials: A concern for three decades. Methods in Information Medicine, 1982, 21, 81–85.
61.Hemminki, E.Quality of reports of clinical trials submitted by the drug industry to the Finnish and Swedish control authorities. European Journal of Clinical Pharmacology, 1981, 19, 157–65.
62.Hemminki, E. Study of information submitted by drug companies to licensing authorities. British Medical Journal, 1980, 833–36.
63.Herxheimer, A.Drug selection and information: Some recommendations from the World Health Organization. Journal of the Royal College of Physicians of London, 1993, 27, 384–85.
64.Herxheimer, A.How much drug in the tablet? Lancet, 1991, 337, 346–48.
65.Hillman, A. L., Eisenberg, J. M., Pauly, M. V., et al. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. New England Journal of Medicine, 1991, 324, 1362–65.
66.Hilts, P. J.Cigarette makers dispute reports on addictiveness. New York Times, 04 15, 1994, Al, A10–A11.
67.Hilts, P. J. Philip Morris blocked paper showing addiction, panel finds. New York Times, 04 1, 1994, A7.
68.Hilts, P. J. Scientists say Philip Morris withheld nicotine findings. New York Times, 04 29, 1994, Al, A7.
69.Hood, J., & William, B.More on sulfinpyrazone after myocardial infarction [editorial]. New England Journal of Medicine, 1982, 306, 988–89.
70.Kassirer, J. P., & Angell, M.Financial conflicts of interest in biomedical research [letter to the editor]. New England Journal of Medicine, 1993, 329, 570–71.
71.Kaufman, D.Cancer therapy and the randomized clinical trial. Cancer, 1993, 72, 2801–04.
72.Koshland, D. E. Jr., Simplicity and complexity in conflict of interest [editorial]. Science, 1993, 261, 11.
73.Lauritsen, K., Havelund, T., Laursen, L. S., & Rask-Madsen, J. Withholding unfavorable results in drug company sponsored clinical trials [letter to the editor]. Lancet, 1987, 1091.
74.Lee, K. L., Calliff, R. M., Simes, J., et al. Holding GUSTO up to the light. Annals of Internal Medicine, 1994, 120, 876–81.
75.Lee, Y. J., Ellenberg, J. H., Hirtz, D. G., & Nelson, K. B.Analysis of clinical trials by treatment actually received: Is it really an option? Statistics in Medicine, 1991, 10, 1595–605.
76.Lerner, M. Jury convicts Garfinkel of 5 fraud accounts. Minneapolis Star, 08 6, 1993, 1A.
77.Liberati, A.Publication bias and the editorial process [letter to the editor]. Journal of the American Medical Association, 1992, 267, 2891.
78.Lock, S., & Wells, F.Fraud and misconduct in medical research. London: BMJ Publishing Group, 1993.
79.Lundberg, G. D.Statement by the International Committee of Medical Journal Editors on duplicate or redundant publication. Journal of the American Medical Association, 1993, 270, 2495.
80.Lurie, P., & Wolfe, S. M.Regulation of benzodiazepine prescription [letter to the editor]. Journal of the American Medical Association, 1992, 268, 472–73.
81.Meier, P.Anturane reinfarction trial [letter to the editor]. New England Journal of Medicine, 1981, 304, 730.
82.Meyers, S., & Janowitz, H. D.The “natural history” of ulcerative colitis: An analysis of the placebo response. Journal of Clinical Gastroenterology, 1989, 11, 33–37.
83.Miller, R. The publication of commercially sponsored supplements [editorial]. Anesthesia and Analgesia, 1993, 77.
84.Moher, D.Clinical trial registration: A call for its implementation in Canada. Canadian Medical Association, 1993, 149, 1657–58.
85.Moher, D., Dulberg, C. S., & Wells, G. A.Statistical power, sample size, and their reporting in randomized controlled trials. Journal of the American Medical Association, 1994, 272, 122–24.
86.Mulrow, C. D.The medical review article: State of the science. Annals of Internal Medicine, 1987, 106, 485–88.
87.Naylor, C. D., Chen, E., & Strauss, B.Measured enthusiasm: Does the method of reporting trial results alter perception of therapeutic effectiveness? Annals of Internal Medicine, 1992, 117, 916–21.
88.Newman, T. B., Browner, W. S., & Hulley, S. B.The case against childhood cholesterol screening. Journal of the American Medical Association, 1990, 264, 3039–43.
89.Nicholson, P. A.Information for drug trial participants [letter to the editor]. Lancet, 1987, 396.
90.Norman, C.Stanford inquiry casts doubt on 11 papers. Science, 1988, 242, 659–61.
91.Office of the Inspector General. Promotion of prescription drugs through payments and gifts. Washington, DC: Department of Health and Human Services, 1991OEI–01–00480.
92.Oxman, A. D.Readers’guide for review articles: Why worry about methods? [editorial]. American College of Physicians Journal Club, 1991, A–12.
93.Oxman, A. D., & Guyatt, G. H.Validation of an index of the quality of review articles. Journal of Clinical Epidemiology, 1991, 44, 1271–78.
94.Oxman, A. D., Guyatt, G. H., Singer, J., et al. Agreement among reviewers of review articles. Journal of Clinical Epidemiology, 1991, 44, 91–98.
95.Pharmaceutical Manufacturers Association. Facts at a glance. Washington, DC: Pharmaceutical Manufacturers Association, 1992.
96.Polis, M. A. Design of a randomized controlled trial of foscarnet in patients with cytomegalovirus retinitis associated with acquired immunodeficiency syndrome. American Journal of Medicine, 1992, 22S–25S.
97.Public Health Service. NIH guidelines on the inclusion of women and minorities as subjects in clinical research. Federal Register, 03 28, 1994, 59, 14508–13.
98.Raju, T. N. K., Langenberg, P., Sen, A., & Aldana, O.How much ‘better’ is good enough? The magnitude of treatment effect in clinical trials. American Journal of the Diseased Child, 1992, 146, 407–11.
99.Rakel, R. E. Antianxiety agents: How to use them, what to avoid. Consultant, 1989, 75–85.
100.Ray, W. A., Griffin, M. R., & Avorn, J.Evaluating drugs after their approval for clinical use [editorial]. New England Journal of Medicine, 1993, 329, 2029–32.
101.Rennie, D.Accountability, audit, and reverence for the publication process [editorial]. Journal of the American Medical Association, 1993, 270, 495–96.
102.Rennie, D.Authorship! Authorship! Guests, ghosts, grafters, and the two-sided coin [editorial]. Journal of the American Medical Association, 1994, 271, 469–71.
103.Rennie, D.Breast cancer: How to mishandle misconduct. Journal of the American Medical Association, 1994, 271, 1205–07.
104.Rennie, D.Editors and auditors [editorial]. Journal of the American Medical Association, 1989, 261, 2543–45.
105.Rennie, D. (ed.) Guarding the guardians: Research on editorial peer review. Journal of the American Medical Association, 1990, 263, 1317–444.
106.Rennie, D.The Second International Congress on Peer Review. Journal of the American Medical Association, 1994, 272, 91–173.
107.Rennie, D., & Bero, L. A.Throw it away Sam: The controlled circulation journals. Council of Biological Editors' Views, 1990, 13, 31–35.
108.Rennie, D., & Flanagin, A.Publication bias: The triumph of hope over experience [editorial]. Journal of the American Medical Association, 1992, 267, 411–12.
109.Review policy for supplement. Cardiovascular Drugs and Therapy, 1993, 7, 493.
110.Ridker, P. M., O'Donnell, C. J., Marder, V. J., & Hennekens, C. H.A response to ‘holding GUSTO up to the light.’ Annals of Internal Medicine, 1994, 120, 882–85.
111.Ridker, P. M., O'Donnell, C.Marder, V. J., & Hennekens, C. H.Large scale trials of thrombolytic therapy for acute myocardial infarction: GISSI–2, ISIS–3, GUSTO–1. Annals of Internal Medicine, 1993, 119, 530–32.
112.Rochon, P. A., Gurwitz, J. H., Cheung, C. M., et al. Evaluating the quality of articles published in journal supplements compared with the quality of those published in the parent journal. Journal of the American Medical Association, 1994, 272, 108–13.
113.Rochon, P. A., Gurwitz, J. H., Simms, R. W., et al. A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis. Archives of Internal Medicine, 1994, 154, 1587–63.
114.Roizon, M. F., (ed). Lessons learned from a phase IV study of propofol: Analysis of data of over 25,000 patients. Anesthesia and Analgesia, 1993, 77, S1–S50.
115.Rothman, K. J.Conflict of interest [editorial]. Journal of the American Medical Association, 1993, 269, 2782–84.
116.Rothman, K. J., & Michels, K. B.The continuing unethical use of placebo controls [editorial]. New England Journal of Medicine, 1994, 331, 394–98.
117.Sackett, D. L., & Gent, M.Controversy in counting and attributing events in clinical trials [editorial]. New England Journal of Medicine, 1979, 301, 1410–12.
118.Schulz, K. F., Chalmers, I., Grimes, D. A., & Altman, D. G.Assessing the quality of randomization from reports of controlled trials published in obstetrics and gynecology journals. Journal of the American Medical Association, 1994, 272, 125–28.
119.Schwarz, R. P. Jr., Maintaining integrity and credibility in industry-sponsored clinical research. Controlled Clinical Trials, 1991, 12, 753–60.
120.Shapiro, M. F. Data audit in investigational drug trials and their implications for detection of misconduct in science. In Lock, S. & Wells, F., (eds.), Fraud and misconduct in medical research, London: BMJ Publishing Group, 1993, 128–41.
121.Simes, R. J.The case for an international registry of clinical trials. Journal of Clinical Oncology, 1986, 4, 1529–41.
122.Smith, J. L., & ACG Committee on FDA-Related Matters. Placebos in clinical trials of peptic ulcer. American Journal of Gastroenterology, 1989, 84, 469–74.
123. Softening the blow of bacterial meningitis. Emergency Medicine, 1989, 45–48.
124.Special Committee on Aging. Prescription drug prices: Are we getting our money’s worth? Washington, DC: United States Senate, 1989, a Majority Staff Report Serial No. 101-D.
125.Special Committee on Aging. The drug manufacturing industry: A prescription for profits. Washington, DC: United States Senate, 1991, Staff Report Serial No. 102-F.
126.Summers, W. K., Majovski, L. V., Marsh, G. M., et al. Oral tetrahydroaminoacridine in long-term treatment of senile dementia. New England Journal of Medicine, 1986, 315, 1241–55.
127.Taylor, S. H., (ed.). A symposium: A new cardiovascular agent with a unique profile. American Journal of Cardiology, 1986, 58, 1E–44E.
128.Temple, R.Difficulties in evaluating positive control trials. Biopharmaceutical Section Proceedings of the American Statistical Association, 1983, 1–7.
129.Temple, R.Government viewpoint of clinical trials. Williamsburg, VA: The Drug Information Association Workshop. 1981, 10–17.
130.Temple, R., & Pledger, G. W.The FDA's critique of the anturane reinfarction trial [special report]. New England Journal of Medicine, 1980, 303, 1488–92.
131.The Anturane Reinfarction Trial Research Group. Sulfinpyrazone in the prevention of sudden death after myocardial infarction. New England Journal of Medicine, 1980, 302, 250–56.
132.The Boston Consulting Group. Executive summary. In The contribution of pharmaceutical companies: What's at stake for America. Boston, MA: The Boston Consulting Group, Inc., 1993.
133.The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. New England Journal of Medicine, 1993, 329, 673–82.
134.Treatment of Mild Hypertension Research Group. A randomized, placebo-controlled trial of a nutritional-hygienic regimen along with various drug monotherapies. Archives of Internal Medicine, 1991, 151, 1413–23.
135.Turner, J. A., Deyo, R. A., Loeser, J. D., et al. The importance of placebo effects in pain treatment and research [review]. Journal of the American Medical Association, 1994, 271, 1609–14.
136.Tversky, A., & Kahneman, D.The framing of decisions and the psychology of choice. Science, 1981, 211, 453–58.
137.Waller, P. C., Wood, S. M., Langman, M. J. S., et al. Review of company postmarketing surveillance studies. British Medical Journal, 1992, 304, 1470–72.
138.Wassertheil-Smoller, S., Blaufox, M. D., Oberman, A., et al. Effect of antihypertensives on sexual function and quality of life: The TAIM Study. Annals of Internal Medicine, 1991, 114, 613–20.
139.Weintraub, M.Regulation of benzodiazepine prescription [letter to the editor]. Journal of the American Medical Association, 1992, 268, 474.
140.Weintraub, M., Singh, S., Byrne, L., et al. Consequences of the 1989 New York State triplicate benzodiazepine prescription regulations. Journal of the American Medical Association, 1991, 266, 2392–97.
141.Weiss, R. B., Vogelzang, N. J., Peterson, B. A., et al. A successful system of scientific data audits for clinical trials: A report from the cancer and leukemia group B. Journal of the American Medical Association, 1993, 270, 459–64.
142.Williams, H. J., Ward, J. R., Reading, J. C., et al. Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. Arthritis and Rheumatism, 1992, 35, 259–69.
143.Winer, N., Carter, C. H., & Eddy, H.Effects of pindolol and methyldopa on blood pressure and plasma norepinephrine. American Heart Journal, 1982, 104, 425–31.
144.World Health Organization. 18th European Symposium on Clinical Pharmacological Evaluation in Drug Control, Bad Neuenahr, December 10–13,1991, World Health Organization, 1993EUR/ICP/DSE 173.
145.World Health Organization. The use of essential drugs, WHO Technical Report Series 825. Geneva: World Health Organization, 1992.
146.Wyllie, E., Pippenger, C. E., & Rothner, A. D.Increased seizure frequency with generic primidone. Journal of the American Medical Association, 1987, 258, 1216–17.